Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 9/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6401187 | 1.00 | CYP2D6 (0.51) | CYP2D6HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL7551792 | 0.88 | ADRA1A (0.48) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL14255244 | 0.88 | HDAC1 (0.44) | CYP2D6HTR1ASLC6A4ADRA1ATAAR1 | |
| SCHEMBL17410211 | 0.87 | CYP2D6 (0.53) | CYP2D6ADRA1ATAAR1HTR2AHTR2C | |
| SCHEMBL594784 | 0.85 | KDM4E (0.46) | HTR1ASLC6A4ADRA1ATAAR1HSD17B10 | |
| SCHEMBL17330013 | 0.83 | HTR1A (0.45) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL15376943 | 0.83 | HTR1A (0.45) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL989673 | 0.81 | TAAR1 (0.66) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL7392254 | 0.81 | KDM4E (0.44) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL12428735 | 0.81 | HTR1A (0.44) | HTR1ASLC6A4ADRA1ATAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |